Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

The Center for Health Outcomes and Population Equity at Huntsman Cancer Institute and the University of Utah, in partnership with the Montana State University Center for American Indian and Rural Health Equity, received a grant for Cancer Control in Persistent Poverty Areas from the National Cancer Institute.

Huntsman Cancer Institute at the University of Utah, a pioneering innovator dedicated to developing more effective ways to care for and prevent cancer, announced plans today for a new Huntsman Cancer Institute comprehensive cancer center in Utah County.

In a recently published manuscript, Howard Colman, MD, PhD, identified a potential breakthrough in glioblastoma treatment.

Huntsman Cancer Institute at the University of Utah, the only place in the region devoted to developing new treatments for cancer, announced the opening of the Kathryn F. Kirk Center for Comprehensive Cancer Care and Women’s Cancers. 

Sagar Patel, MD, discusses how the timing of autologous stem cell transplant can affect outcomes in those with myelofibrosis, including the risk of patients developing post-transplant complications.

Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.

Neeraj Agarwal, MD, is now a distinguished member of the Fellows of the American Society of Clinical Oncology.

Brian Mitzman, MD, FACS, FCCP, discusses the use of adjuvant atezolizumab following platinum-based chemotherapy in patients with resectable non–small cell lung cancer.

TALAPRO-2 demonstrated that using talazoparib in combination with enzalutamide may reduce the risk of disease progression or death by 37%.

Brian Mitzman, MD, FACS, FCCP, discusses the emergence of immunotherapy as a treatment option for patients with early-stage non–small cell lung cancer.

Amandeep Godara, MBBS, discusses CAR T-cell therapies currently available for patients with multiple myeloma.

Varghese, known for his innovative research in perioperative care and mentorship to physician-scientists, will become SUS President in February 2024.

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

Brian Mitzman, MD, FACS, FCCP, discusses findings from the phase 3 CheckMate 816 trial in patients with resectable non–small cell lung cancer.

Amandeep Godara, MBBS, discusses the evolving treatment landscape in both early and late relapsed multiple myeloma, updated clinical trial results with CAR T-cell therapy, and key considerations when navigating treatment selection in this disease space.

Amandeep Godara, MBBS, expands on the advantages and limitations of teclistamab monotherapy in patients with late-relapsed myeloma, discusses the best use of bispecific antibodies and CAR T-cell therapy in this population, and highlights ongoing efforts to mitigate the impact of treatment-related toxicities and improve accessibility across the paradigm.

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

Huntsman Cancer Institute at the University of Utah congratulates three of their newest endowed chairs.

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.

Sagar Patel, MD, discusses complications following allogeneic stem cell transplant that can occur in patients with myelofibrosis.

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

Findings from the MASTER trial in multiple myeloma could help shape how future treatment decisions are approached for fit, transplant-eligible patients.

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.